BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Franken MD, de Hond A, Degeling K, Punt CJA, Koopman M, Uyl-de Groot CA, Versteegh MM, van Oijen MGH. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. Health Qual Life Outcomes 2020;18:240. [PMID: 32690011 DOI: 10.1186/s12955-020-01481-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Sun S, Jonsson H, Salén KG, Andén M, Beckman L, Fransson P. Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost-utility analysis alongside a randomized HYPO-RT-PC trial. Eur J Health Econ 2022. [PMID: 35587847 DOI: 10.1007/s10198-022-01467-5] [Reference Citation Analysis]
2 Jansen F, Verdonck-de Leeuw IM, Gamper E, Norman R, Holzner B, King M, Kemmler G; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D. Qual Life Res 2021;30:2009-19. [PMID: 33512653 DOI: 10.1007/s11136-021-02767-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]